Urinary Kininogen-1 and Retinol binding protein-4 respond to Acute Kidney Injury: Predictors of patient prognosis? by Gonzalez-Calero, Laura et al.
1Scientific RepoRts | 6:19667 | DOI: 10.1038/srep19667
www.nature.com/scientificreports
Urinary Kininogen-1 and Retinol 
binding protein-4 respond to Acute 
Kidney Injury: predictors of patient 
prognosis?
Laura Gonzalez-Calero1, Marta Martin-Lorenzo1, Angeles Ramos-Barron2, Jorge Ruiz-Criado2, 
Aroa S. Maroto1, Alberto Ortiz3, Carlos Gomez-Alamillo2, Manuel Arias2, Fernando Vivanco1,4 
& Gloria Alvarez-Llamas1
Implementation of therapy for acute kidney injury (AKI) depends on successful prediction of individual 
patient prognosis. Clinical markers as serum creatinine (sCr) have limitations in sensitivity and early 
response. The aim of the study was to identify novel molecules in urine which show altered levels in 
response to AKI and investigate their value as predictors of recovery. Changes in the urinary proteome 
were here investigated in a cohort of 88 subjects (55 AKI patients and 33 healthy donors) grouped 
in discovery and validation independent cohorts. Patients’ urine was collected at three time points: 
within the first 48 h after diagnosis(T1), at 7 days of follow-up(T2) and at discharge of Nephrology(T3). 
Differential gel electrophoresis was performed and data were confirmed by Western blot (WB), liquid 
chromatography/mass spectrometry (LC-MS/MS) and enzyme-linked immunosorbent assay (ELISA). 
Retinol binding protein 4 (RBP4) and kininogen-1 (KNG1) were found significantly altered following AKI. 
RBP4 increased at T1, and progressively decreased towards normalization. Maintained decrease was 
observed for KNG1 from T1. Individual patient response along time revealed RBP4 responds to recovery 
earlier than sCr. In conclusion, KNG1 and RBP4 respond to AKI. By monitoring RBP4, patient’s recovery 
can be anticipated pointing to a role of RBP4 in prognosis evaluation.
Acute kidney injury (AKI) is a multifactorial syndrome, a frequent clinical complication in hospitalized patients 
and responsible of a substantial morbidity and mortality1,2. Serum creatinine (sCr) is the reference standard 
for AKI diagnosis, but lacks sensitivity, may be delayed in response to injury (retrospective indicator), and is 
influenced by independent factors. As result, current diagnosis is often delayed in time, limiting the possibility 
of earlier intervention and promoting adverse outcomes. AKI may progress to chronic kidney disease (CKD), 
CKD itself is a risk factor for AKI in CKD patients, and AKI may accelerate CKD progression. In fact a substantial 
proportion of AKI patients in daily clinical practice have underlying CKD. In this context, design of novel thera-
peutic strategies aimed at limiting kidney injury and preventing AKI progression requires novel biomarkers that 
allow early monitoring of kidney damage and helping in prognosis prediction3,4.
Urine represents a combination of both plasma ultrafiltrate and urinary tract proteins, including glomeru-
lar filtrated plasma proteins, soluble proteins secreted by tubular epithelial cells and microvesicles as exosomes. 
Thus, urine composition not only reflects normal kidney function but also contains specific kidney produced 
proteins which may be altered in response to underlying physiopathology5. Urine has been investigated to study 
renal physiology and kidney diseases6. Our group have investigated urine in the search for novel molecular tar-
gets of potential use in the clinical setting from a diagnosis or prognosis point of view in the context of diabetic 
nephropathy7, chronic kidney disease8, and cardiovascular disease9. Here, we pursued the identification of major 
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molecular alterations in urine in response to AKI in the search for novel indicators. Their capability to monitor 
recovery from AKI and thus predict patient’s prognosis will be also evaluated.
Results
Urinary RBP4 and KNG1 proteins are identified as main responders to AKI. Table 1 depicts 
demographic and clinical characteristics of participants. Individual data are included in Supplementary Tables. 
Principal component analysis (Fig. 1A) revealed a clear differentiation between controls and cases with a slight 
trend towards recovery gradually over time for a sub-group of individuals. Differential statistical analysis revealed 
Retinol binding protein 4 (RBP4) and Kininogen 1 (KNG1) as main molecular responders to AKI condition 
(Fig. 1B and Table 2). RBP4 is increased significantly in the first sample (T1) compared to control values, and 
remains significantly higher at T2. Inter-individual variability was particularly observed at nephrological dis-
charge (T3). The opposite trend was observed for KNG1, decreasing its urinary concentration in response to 
AKI from the first time point evaluated (T1). At discharge, KNG1 urinary levels remain considerably lower than 
control values.
In the confirmation cohort, target analysis of urinary RBP4 and KNG1 was performed by liquid chromatog-
raphy mass spectrometry in selected reaction monitoring mode (SRM-LC-MS/MS) for validation. In this case, 
individual urine samples were analyzed to assess individual behavior (molecular response). Again, significant 
differences were observed between control group and AKI patients for RBP4 and KNG1 (Fig. 2) in the first 48 h 
and follow-up, confirming previously observed trends by differential gel electrophoresis (DIGE) and the response 
of these two proteins (RBP4 increase and KNG1 decrease) to AKI. This response was further evaluated by ROC 
curves, resulting in areas under the curve (AUC) higher than 0.9 in both cases (see Fig. 2). While average KNG1 
levels do not return to control values at discharge, there is a clear trend towards normalization in the case of RBP4 
(Fig. 2).
RBP4 in urine responds to patient’s recovery earlier than sCr clinical marker. To further inves-
tigate a potential prognostic value for RBP4, we analyzed individual samples collected from a new randomized 
cohort of a total of 23 patients and 13 healthy subjects by WB. Thirteen of those 23 patients could be monitored 
at the three time points. On average, including all patients monitored (and not only those for whom sampling 
was possible at the three time points), RBP4 increased significantly at T1 and progressively decreased thereafter 
Characteristics N (%)
Age, years 64 ± 16† (15–84)
Men 37 (67.3)
Comorbidities
 Hypertension 41 (74.5)
 Diabetes mellitus 21 (38.2)
 Cardiovascular disease 28 (50.9)
 Chronic kidney disease 16 (29.1)
Charlson comorbidity score 5.6 ± 3.4†
ISI comorbidity score 0.28 ± 0.19†
Nephrotoxic drugs (≥ 1) 47 (85.5)
Type of admission
 Medical 39 (70.9)
 Surgical 16 (29.1)
ICU stage 12 (21.8)
Etiology of acute kidney disease
 Pre-renal 28 (50.9)
 Acute tubular necrosis 27 (49.1)
AKI–KDIGO at diagnosis
 1 5 (9.1)
 2 9 (16.4)
 3 41 (74.5)
Peak sCr 8.1 ± 4.7†
Length of stay, days 9 (8)*
Dialysis required 15 (27.3)
Oliguria (≤ 400 mL/24 h) 10 (20)
Full recovery of renal function at discharge 17 (34.7)
Hospital mortality 3 (5.5)
Mortality at one year 7 (12.7)
Table 1.  Demographics characteristics of patients included in the study. *Expressed as median and 
interquartile range. †Expressed as mean ± SD.
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towards normalization, as expected in view of DIGE and SRM data (Fig. 3A). Persistent decrease in KNG1 was 
observed from T1 (Fig. 3B).
In a further step, patients’ response was analyzed individually in view of their recovery. In daily clinical prac-
tice a substantial proportion of AKI patients have underlying CKD (30% in our series) as does a significant pro-
portion of the general population (around 10%)10. Thus, inclusion of CKD patients, as in this study, represents 
the AKI patients clinicians are dealing with11. Lack of clinical recovery means that CKD may have developed (if 
there was no prior CKD) or that CKD has progressed (in patients with prior CKD). Both outcomes are associated 
with impaired vital outcomes, and early prediction of de novo or worsening CKD may be equally useful to iden-
tify a high risk population that may be enrolled in future clinical trials. In this study, recovery means sCr values 
≤ 1.3 mg/dL by T3 for non-CKD patients of returning to basal levels for CKD individuals, according to clinical 
criteria. Figure 4A represents those patients who clinically recover later than T3 according to sCr values, show-
ing normalized RPB4 values (no significant differences between C and T3) already at T3. Individual response 
of urinary RBP4 also shows a decreasing trend towards control values after AKI for those patients who recover 
(Fig. 4B). Patients with sCr(T3) ≤ 1.3 mg/dL already showed RBP4 values close to controls at this time point 
(Fig. 4B, dashed lines), while in patients who do not recover urinary RBP4 is persistently high (Fig. 4B, insert). 
These results were further confirmed by ELISA as can be seen in Supplementary Figure 3. RBP4 is, thus, able to 
show patient’s recovery earlier than sCr.
Discussion
The human urinary proteome was here first investigated in the search for significantly altered molecules in 
response to AKI12. Prior studies point to the need of defining marker panels preferably than individual diagnostic 
Figure 1. Proteins significantly altered in urine in response to AKI. (A) Principal component analysis 
(PCA) graph resulting from the DIGE analysis show clear grouping of control subjects and AKI patients. Each 
dot represents a pool sample made of urine aliquots from 4 individuals. Urine was collected from a total of 20 
healthy subjects (C) and 20 patients at three different time points (T1, T2 and T3). Arrows point to individuals 
showing trend of partial recovery. (B) Standardized Log Abundance found corresponding to protein spots of 




1-ANOVAT-test Av.Ratio T-test Av.Ratio T-test Av.Ratio
KNG1 0.001 − 9.13 0.009 − 5.57 0.07 − 5.76 0.0004
RBP4 0.0008 19.06 0.009 15.69 0.1 9.93 0.0008
Table 2. T-Test and average data values for RBP4 and KNG1 protein spots as main significantly varied 
proteins over time in response to AKI.
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molecules to better assess the complex AKI/CKD syndromes13. Proteomics approaches provide non-biased infor-
mation on the protein changes in a biological fluid as a whole, without pre-selection of potential targets of interest. 
DIGE technology was chosen here for the discovery phase, based on its proved value as a differential proteomics 
strategy for proteins quantification in biological samples in the search for markers of disease (cardiovascular dis-
ease, kidney disease, cancer and neurodegenerative diseases, among others), by our group and others3,14–19. KNG1 
and RBP4 were found here as responders to AKI from the first sample obtained within 48 h of nephrological 
diagnosis. These data were confirmed in an additional cohort of individuals and prompted the development of a 
specific mass spectrometry-based quantitative method specifically developed for high-throughput assessment of 
KNG1 and RBP4 proteins in urine, in a manner which may offer a future reliable quantitative assay which may be 
Figure 2. Urinary RBP4 (A) and KNG1 (B) analysis by (SRM)LC-MS/MS. Transitions shown 
(precursor→ fragment) are: 813.48-> 970.60 (RBP4) and 713.70-> 956.0 (KNG1). A different cohort of 
individuals to that used in DIGE analysis was recruited. Increased urinary levels for RBP4 in response to 
AKI were confirmed. Error bars show standard error of media. ROC curves showing response to AKI were 
calculated for RBP4 (C) and KNG1 (D). *p value ≤ 0.05; **p value ≤ 0.01; ***p value ≤ 0.001;  
****p value ≤ 0.0001.
Figure 3. Western blot data for RBP4 performed with individual urine samples. A different cohort of 
individuals to that used in DIGE analyses was recruited. On average, increased urinary levels for RBP4 (A) 
and decreased urinary levels for KNG1 (B) in response to AKI was confirmed: graphs show average data for all 
patients monitored (recovered at any time point or not). *p value ≤ 0.05; **p value ≤ 0.01; ***p value ≤ 0.001; 
****p value ≤ 0.0001.
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competitive in the clinical setting. Not only earlier diagnosis but also outcome prediction after an AKI episode is 
of enormous interest. Insulin-like growth factor-binding protein 7 (IGFBP-7) was recently identified in urine as a 
prognostic marker3 and, here, the capacity to anticipate patient’s recovery earlier than traditional markers as sCr 
was further evaluated and confirmed for RBP4.
KNG1and RBP4 genes were two of the top kidney up-regulated ones in an end stage renal disease (ESRD) 
mouse model20. We show here a significant decrease in urinary KNG1 in response to AKI. Kininogen is a pre-
cursor of kinins from the kallikrein-kinin system. When this cascade is activated, the serine protease kallikrein 
(tissue or plasma) processes kininogen (low or high molecular weight) to produce vasoactive peptides (e.g. brady-
kinin (BK)) which are involved in blood pressure regulation, renal and cardiac function and inflammation among 
other physiological and pathological processes21,22. In a salt-induced hypertension rat model, tissue kallikrein/
kinin infusion reversed kidney injury, inflammation and fibrosis23 pointing to a protective role for this metabolic 
cascade24,25. In hypertensive subjects, urinary kininogen and kinins were decreased, while excretion of kallikrein 
was normal. However, in end-stage renal disease, kinins and kallikrein were decreased and a normal excretion 
of kininogen was found26. In IgA nephropathy patients, urinary kininogen excretion was found significantly 
different for responders and non-responders to an angiotensin-converting-enzyme inhibitor (ACE-inhibitor) 
therapy27, which may be in alignment with the reported variants of kininogen gene influencing individual 
response to aldosterone28. To our best knowledge, urinary KNG1 has not been directly related to AKI in humans. 
T-Kininogen was found differentially expressed in rats after cisplatin or ischemia/reperfusion treatment29. In 
response to streptozotocin-induced diabetes in rats, kininogen, kallikrein, BK levels and BK B1- and B2-receptor 
expression were decreased in glomeruli and in cultured podocytes, implying a role for kallikrein-kinin system in 
podocyte apoptosis in diabetic conditions30. Plasma high molecular weight kininogen increased in accordance 
to progressive renal function worsening in microalbuminuric diabetic patients31, the opposite trend to what pre-
viously reported in urine. However, plasma kininogen was decreased in biopsy confirmed acute rejection after 
renal transplantation32, following the same trend that urine kininogen in response to kidney chronic allograft 
dysfunction33. These two studies are in consonance with our findings. Despite these studies, the participation 
and specific role of the molecules constituting the kallikrein-kinin system in a wide variety of clinical contexts 
are underexplored. Nevertheless, there are enough evidences to propose a link between kininogen expression and 
kidney injury (e.g. AKI, rejection following transplantation), loss of renal function, hypertension or albuminuria 
progression.
We also found increased urinary levels of RBP4 in response to AKI. The rise was observed from the first 48 h 
of nephrological diagnosis and maintained at discharge on average, although individual differences were further 
explored and confirmed related to recovery. This low molecular weight protein is easily filtered by the glomer-
ulus and reabsorbed for the most part in proximal tubules. It has been proposed as the best indicator of tubular 
dysfunction, as a minor reduction in tubular function may lead to increased RBP4 excretion. In consequence, 
urinary RBP4 level has been proposed as the most sensitive biomarker for loss of proximal renal tubule function 
in humans34. In response to acute kidney allograft injury, RBP levels increased in urine35. In a follow-up study of 
kidney transplantation prognosis in the following year, RBP predicted graft loss independently of histology and 
urinary albumin36. Increased levels of RBP4 in diabetic patients with further increased observed in presence of 
microalbuminuria pointed to an incipient nephropathy in this clinical group37. In this context, RBP4 has been 
proposed as a marker of risk of developing CKD of macroalbuminuric diabetic nephropathy patients38.Other 
studies observed altered RBP4 levels in diabetic patients with tubular injury, although it is unclear whether it 
predicts microalbuminuria development39–41. Related to AKI, there is increasing interest in further investigating 
the role of RBP4 in early diagnosis. Data shown here give further evidence of the RBP4 (reversible) response to 
the AKI clinical condition, showing increased urinary RBP4 levels in AKI patients. Furthermore, RBP4 response 
in urine tends to normalize with time for those patients who progressively recover in terms of sCr, however RBP4 
Figure 4. WB data for RBP4 and KNG1 for patients who clinically recovered later than T3 according to 
sCr. Normalization of RPB4 levels was observed already at T3 on average (A,B) Individual RBP4 responses for 
those patients monitored at the three time points (solid lines represent patients with sCr(T3) > 1.3 mg/dL and 
dashed lines represent patients with sCr(T3) ≤ 1.3 mg/dL). Inset shows representative behavior of RBP4 for 
patients who do not recover. **p value ≤ 0.01.
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remains persistently high in those patients who do not recover. More importantly, RBP4 responds earlier than sCr 
does on average and allows monitoring individual response and further predict future recovery.
The coexistence of common mechanisms in different renal disorders with subjacent complex cellular 
responses taking place simultaneously make the specific identification of biomarkers of AKI, allograft dysfunc-
tion, diabetic renal complications or CKD development a real challenge. Some of the proposed biomarkers in the 
literature are in fact coincident in various diseases42.
The use of panels of biomarkers to the detriment of individual molecules should be explored to improve accu-
racy and specificity. A specific assay for these RBP4 and KNG1 proteins quantitation, based on SRM methodology, 
was here developed which enormously facilitates feasibility in the clinic in terms of sensitivity and throughput.
One limitation of the study may be the number of recruited subjects, wide distribution for age, diabetes, 
hypertension or drugs. On the other hand, serum creatinine (sCr) and urinary output are the key clinical tools 
to define AKI. However, assessment of urinary output is more prone to error, especially in patients without an 
indwelling bladder catheter43. Thus and in order to reflect daily clinical situation in many non-intensive care 
units (ICU), we relied on serum creatinine criteria for diagnosis of AKI. DIGE also has known weaknesses to 
be acknowledged, such as poor coverage of low abundance proteins or very hydrophobic proteins. On the other 
hand, urine has enormous potential as non-invasive fluid able to reflect changes in renal function or injury, but 
the variability in protein content may be considerable and this fact implies normalization to e.g. urinary creati-
nine or total protein content. Finally, real clinical translation of a novel identified marker is so far hampered by 
significant difficulties. In general, the biomarker pipeline from identification to final implementation should go 
through several essential process phases: candidate discovery, qualification, verification, research assay optimi-
zation, biomarker validation, commercialization and widespread implementation in routine clinical practice44,45. 
Currently, no novel biomarker has progressed to all those stages in AKI. In particular, AKI occurs in a wide vari-
ety of clinical scenarios, thus assessing the real-life performance of a proposed marker implies prior testing of its 
sensitivity/specificity and capacity of prediction in these various clinical conditions46.
Conclusions
Urinary KNG1 and RBP4 clearly respond to AKI. Additionally, RBP4 could predict recovery by monitoring this 
protein levels over time after AKI, as RBP4 reflects patient’s normalization earlier than sCr values do. Further 
evaluation of KNG1 and RBP4 diagnostic and prognostic value should follow (e.g. in a prospective study where 
their role in earlier diagnosis could be investigated), alone or in combination with other proposed markers.
Methods
Subjects recruitment and urine samples collection. Urine samples from 55 AKI patients without pro-
teinuria, diagnosed by Nephrology Department staff, were collected at Hospital Valdecilla (Santander, Spain) at 
three time points: diagnosis within the first 48 h (T1), at 7 days of follow-up (T2) and at Nephrology discharge 
(T3). AKI was defined and classified according KDIGO criteria47. Peak sCr was considered as the highest value 
of sCr after diagnosis. Recovery was considered, as suggested by ADQI guidelines, when sCr was ≤ 1.3 mg/dL 
in patients without previous CKD or return to baseline values in case of CKD. Patients were ramdomized and 
samples from 20 patients were used in a first discovery phase, and samples from 35 patients were recruited for 
confirmation studies. Urine samples were also collected from 33 healthy donors (mean age 47.9 ± 12 (26–65), 
without comorbidities and normal renal function) (20 for the discovery phase and 13 for confirmation). Existence 
of cardiovascular disease (CVD), CKD, hypertension (HTN) or diabetes mellitus was assessed. Spot urine sam-
ples were obtained from a morning random-catch sample, collected in a sterile container, centrifuged to remove 
cell debris (3000 rpm, 10 min) (Centrifuge Sorvall T6000D), and the supernatant frozen at − 80 °C until analysis.
Ethics, consent and permissions. Sample collection procedures were in accordance with the Helsinki 
declaration and signed informed consent was obtained. Approved consent was obtained from Ethical Committee 
for Clinical Research from Cantabria (CEIC, Comité de Ética e Investigación Clínica), endorsed by IDIVAL.
Unbiased proteomics analysis by Differential Gel Electrophoresis (DIGE). Differential protein 
analysis was performed by DIGE (GE Healthcare® ). A total of 20 AKI patients and 20 control subjects were used 
in this first discovery phase, to identify strongest protein alterations in urine in response to AKI. Four individual 
urine samples from each group were pooled, making a total of 5 pools to be analysed per group (C, T1, T2 and 
T3). 5 nmol CyDye DIGE Fluor labelling kit (GE Healthcare) was used to label proteins following manufacturer’s 
instructions. Labelled samples were loaded onto IPG strips (24 cm, pH 4–7) and isoelectric focusing (IEF) was 
carried out in a PROTEAN IEF CELL (BioRad)14. Second dimension was carried out on 14% running gels using 
EttanDaltSix System (GE Healthcare). Gels were scanned using a Typhoon 9400 Variable Mode Imager (GE 
Healthcare) and spot maps were processed, analyzed and compared using the DeCyder Differential Analysis 
Software version 6.5 (GE Healthcare). Spot detection and normalized volume ratio calculations were performed 
in the Differential In-gel Analysis (DIA) module, while gel-to-gel matching and statistical analysis were per-
formed in the Biological Variation Analysis (BVA) module. A first ANOVA test was performed (including FDR) 
followed by Student’s t test for pairs comparisons of the expression data of each spot.
MALDI-TOF Mass Spectrometry identification of candidate markers of AKI. Spots selected for 
analysis were in-gel reduced, alkylated and digested with trypsin according to Sechi and Chait48. Supernatants 
were spotted onto a matrix assisted laser desorption ionization (MALDI) target plate. 0.5 μ l of a 3 mg/ml of 
α -cyano-4-hydroxy-cinnamic acid matrix in 0.1% trifluoroacetic acid-50% acetonitrile was added to the dried 
peptide digest spots. Samples were analyzed using MALDI-time of flight (TOF/TOF) mass spectrometer 4800 
plus Proteomics Analyzer (Applied Biosystems. MDS Sciex, Toronto, Canada) and 4000 Series Explorer™ v 3.5 
Software (ABSciex). GPS explorer v 3.5 (ABSciex) software was used for spectra analyses and generating peaking 
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lists. Searches for peptide mass fingerprints, tandem MS spectra and both combined were performed in the 
NCBInr database using Mascot v.2.2 from Matrix Science (http://www.matrixscience.com). In all identified pro-
teins, the probability score was greater than the one fixed by Mascot as being significant, that is, a p value under 
0.05.
Urinary RBP4 and KNG1 targeted analysis by Selected Reaction Monitoring (SRM) LC-MS/MS. 
As previously published by our group and others7,9,49, we used SRM-LC-MS/MS to validate differential proteins 
identified in the discovery phase. Urine samples from different individuals’ cohorts were used. In particular, 
16 patients and 7 healthy subjects were recruited. Urine samples were concentrated and desalted. Total protein 
content was quantified by Bradford assay and protein samples were reduced, alkylated and digested with sequenc-
ing grade trypsin (Roche). Tryptic peptides solutions were cleaned with C18 spin columns (Protea Biosciences) 
according to manufacturer’s instructions and mixed 1:1 with mobile phase A (0.1% formic acid in MilliQ 
water). A 6460 Triple Quadrupole mass spectrometer was used on-line connected to nano-chromatography in 
a Chip-format configuration (ChipCube interface, ProtID Zorbax 300B-C18-5 μ m chip, 43 × 0.075-mm analyt-
ical column and 40 nL enrichment column, Agilent Technologies). The system was controlled by Mass Hunter 
Software (v4.0 Agilent Technologies). Theoretical SRM transitions were designed using Skyline (v.1.1.0.2905) and 
peptide specificity was confirmed by protein blast. Only those proteotypic (specific) peptides were selected50. In 
this case, one specific proteotypic peptide was measured per protein, by monitoring two transitions for RBP4 and 
three transitions for KNG1 (see Supplementary material).
Urinary RBP4 and KNG1 assessment by Western blot and ELISA. A different cohort to that used in 
the discovery phase was recruited for confirmation of candidate markers by WB. 10 mL urine samples were col-
lected from 23 AKI patients and 13 healthy individuals. The same amount of total protein (10 μ g) total protein was 
dissolved in Laemmli buffer and loaded per lane in a 12% acrylamide gel (4% stacking). Membranes were blocked 
with PBS containing 7.5% non-fat dry milk powder and 0.1% Tween-20 for 1 h at room temperature. Membranes 
were then incubated for 1 h with specific primary antibody rabbit monoclonal anti-KNG1 (1:5000) (Abcam) or 
with rabbit monoclonal anti-RBP4 (1:50000) (Abcam) in phosphate buffered saline in Tween-20 (PBS-T) (0.05%) 
containing 5% non-fat dry milk. Finally, they were incubated with horseradish peroxidase (HRP)-conjugated 
rabbit TrueBlot® (1:1000) (Rockland) for KNG1 or HRP-conjugated goat anti-rabbit (1:10000) (Nordic) for RBP4 
as secondary antibody, in PBS-T (0.05%) containing 5% non-fat dry milk. Detection was performed by enhanced 
chemiluminescence (ECL kit; GE Healthcare) following the instructions of the manufacturer. Protein bands were 
quantified by ImageJ software.
Concentration of RBP4 was additionally measured by ELISA in urine from a cohort of 8 control subjects and 
8 AKI patients following manufacturer’s instructions (Abcam, ab108897).
Statistical analysis. Statistical analyses were performed using SPSS, v15.0 (SPSS Inc., Chicago, IL, USA), 
and GraphPad Prism 6 (version 6.01) software. The Kolmogorov-Smirnov test (KS) was used to assess the normal 
distribution of clinical variables. Quantitative variables were expressed as mean ± standard deviation (SD) or 
median and interquartile range (IR) for variables with non-normal distribution. Kruskal-Wallis with Dunn’s mul-
tiple comparisons test was calculated and differences were considered significant when p value < 0.05. For receiver 
operating characteristic (ROC) curve, assessment confidence level was selected as 95% and p value < 0.0001.
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